Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Moleculin Biotech (MBRX) Return on Capital Employed (2016 - 2025)

Moleculin Biotech's Return on Capital Employed history spans 10 years, with the latest figure at 1.74% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 1.74% for Q4 2025, up 5.0% from a year ago — trailing twelve months through Dec 2025 was 1.74% (up 5.0% YoY), and the annual figure for FY2025 was 1.98%, down 78.0%.
  • Return on Capital Employed for Q4 2025 was 1.74% at Moleculin Biotech, down from 1.58% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.23% in Q2 2021 to a low of 2.15% in Q1 2025.
  • The 5-year median for Return on Capital Employed is 0.72% (2023), against an average of 0.93%.
  • The sharpest move saw Return on Capital Employed soared 57bps in 2021, then tumbled -119bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.28% in 2021, then tumbled by -95bps to 0.54% in 2022, then crashed by -71bps to 0.92% in 2023, then crashed by -95bps to 1.8% in 2024, then grew by 3bps to 1.74% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 1.74%, 1.58%, and 1.9% for Q4 2025, Q3 2025, and Q2 2025 respectively.